GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (FRA:DUL) » Definitions » Net Margin %

Alnylam Pharmaceuticals (FRA:DUL) Net Margin % : -13.34% (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Alnylam Pharmaceuticals's Net Income for the three months ended in Mar. 2024 was €-61 Mil. Alnylam Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was €455 Mil. Therefore, Alnylam Pharmaceuticals's net margin for the quarter that ended in Mar. 2024 was -13.34%.

The historical rank and industry rank for Alnylam Pharmaceuticals's Net Margin % or its related term are showing as below:

FRA:DUL' s Net Margin % Range Over the Past 10 Years
Min: -1016.58   Med: -474.6   Max: -16.58
Current: -16.58


FRA:DUL's Net Margin % is ranked better than
68.99% of 1032 companies
in the Biotechnology industry
Industry Median: -156.25 vs FRA:DUL: -16.58

Alnylam Pharmaceuticals Net Margin % Historical Data

The historical data trend for Alnylam Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Net Margin % Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -403.24 -174.15 -101.01 -109.04 -24.08

Alnylam Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.53 -86.59 19.69 -31.35 -13.34

Competitive Comparison of Alnylam Pharmaceuticals's Net Margin %

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Net Margin % falls into.



Alnylam Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Alnylam Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-403.702/1676.544
=-24.08 %

Alnylam Pharmaceuticals's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin=Net Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-60.66/454.786
=-13.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alnylam Pharmaceuticals  (FRA:DUL) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Alnylam Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals (FRA:DUL) Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (FRA:DUL) Headlines

No Headlines